Effect of Statin Therapy on C-Reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

• Status: Unknown status
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Loma Linda Health Care System
• Treatments: Simvastatin

Criteria

Inclusion Criteria:

• Medically optimized COPD patients

• Age 40-79 years.

• serum CRP levels >3mg/l

Exclusion Criteria:

• Current smoker

• COPD exacerbation in the last 2 months.

• Active hepatic or severe renal dysfunction.

• connective tissue disease, chronic inflammatory disease, malignancy, any acute illness, leukocytosis (>10,000 white blood cells) or thrombocytosis (>450,000 platelets).

• Recent h/o myocardial infarction, angina in the last 6 months.

• Pregnancy.